Timeline
Gilead pays $7.8bn to take full control of a CAR T therapy that could win FDA approval by year-end
Injecting mitochondria from the young into the old
Hims & Hers to buy Eucalyptus for $1.15 billion
Lilly’s AI Factory Could Redefine How We Make Medicine
More in AI
Buying AI software will not fix your business, HBR podcast warns
Harvard Business Review's Josh Tyrangiel says organisations must define the problem before adopting artificial intelligence, not after.